Opendata, web and dolomites

G125 SIGNED

A minimally invasive, outpatient treatment for Gastroesophageal Reflux Disease (GERD), resulting in permanent relief from both GERD symptoms and life-long drug dependency

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 G125 project word cloud

Explore the words cloud of the G125 project. It provides you a very rough idea of what is the project "G125" about.

fibro    consists    prepare    injectable    catheter    inhibitors    esophagal    daily    area    agent    root    thereby    ascentx    endoscopic    elongated    trial    scaffold    suspended    severe    union    pump    gerd    least    strategy    commercialization    biocompatible    invasive    content    underlying    caused    gastroenterological    microspheres    gastro    outpatient    mask    option    million    symptoms    innovation    procedure    medications    surgical    treatment    tissue    ingrowth    acid    12    plan    patients    gastric    esophageal    polymethylmethcrylate    syringe    followed    chain    barrier    enzymes    les    20    cure    uses    ppis    regurgitation    normal    heartburn    proton    disease    transition    bore    responders    gastroesophageal    unfortunately    15    medication    clinical    flexible    lower    bovine    disorder    drafted    sphincter    collagen    g125    bulking    diagnosis    debilitating    supply    stimulated    treat    made    market    efs    sufferers    vascular    needle    refine    anti    reflux    cell    perform    injection    medical    pmma    intervention    integrity    people    permanent    digestive   

Project "G125" data sheet

The following table provides information about the project.

Coordinator
ASCENTX MEDICAL EUROPE LIMITED 

Organization address
address: UNIT 6 QUEENS YARD, WHITE POST LANE
city: LONDON
postcode: E95EN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://ascentxmedical.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASCENTX MEDICAL EUROPE LIMITED UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Gastroesophageal Reflux Disease (GERD) is a digestive disorder associated with symptoms such as heartburn and regurgitation, and reflux of normal gastric content like gastric acid and digestive enzymes. GERD is caused by a loss of integrity of the gastro-esophageal barrier known as the 'lower esophageal sphincter' (LES). This condition is one of the most common gastroenterological diagnosis in the European Union, with an estimated 15-20 Million daily sufferers. GERD today is typically treated with medications such as proton pump inhibitors (PPIs). Unfortunately, these anti-acid medications only ‘mask’ GERD symptoms, cause severe side-effects long-term, and about 20% of patients are non-responders. Importantly, they do not treat/cure the underlying root cause of acid reflux. For people who have severe GERD and do not respond to medication, invasive surgical intervention remains the only option. G125 is the least invasive outpatient treatment for Gastroesophageal Reflux Disease (GERD). It is a permanent injectable bulking agent for the endoscopic treatment which enables cell growth in the Lower Esophagal Sphincter (LES), thereby providing long term cure for the debilitating symptoms of GERD. G125 uses a tissue-friendly (biocompatible) microspheres made of Polymethylmethcrylate (PMMA) suspended in bovine collagen and an Elongated Flexible Syringe (EFS) which consists of an elongated catheter and a transition bore needle. The PMMA microspheres provide a permanent scaffold for stimulated fibro-vascular tissue ingrowth in the affected area. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Within the overall innovation project AscentX Medical will refine the endoscopic injection procedure, perform a 12 month clinical trial with 60 patients followed by a scale up of the production to prepare for commercialization.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "G125" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "G125" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

Click and Spray (2020)

A SIMPLER, CHEAPER AND EASIER TO RECYCLE AEROSOL CONTAINER

Read More